Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases-Reference-Cited by-同舟云学术

Severe hypersensitivity reactions to biological drugs in children with rheumatic diseases

Published:2019-09-08 Issue:8 Volume:30 Page:833-840
ISSN:0905-6157
Container-title:Pediatric Allergy and Immunology
language:en
Short-container-title:Pediatr Allergy Immunol

Author:

Soyer Ozge¹^ORCID,Demir Selcan²,Bilginer Yelda²,Batu Ezgi Deniz²,Sonmez Hafize Emine²,Arıcı Zehra Serap²,Şahiner Ümit Murat¹^ORCID,Sekerel Bulent Enis¹^ORCID,Ozen Seza²

Affiliation:

1. Department of Pediatrics Division of Allergy Hacettepe University School of Medicine Ankara Turkey

2. Department of Pediatrics Division of Rheumatology Hacettepe University School of Medicine Ankara Turkey

Publisher

Wiley

Subject

Immunology,Immunology and Allergy,Pediatrics, Perinatology, and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/pai.13114

Reference30 articles.

1. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

2. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

3. Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis

4. Anti-TNF therapy: past, present and future

5. Management of rheumatic disease with comorbid HBV or HCV infection

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immediate Hypersensitivity Reactions to Biologic Drugs in Children with Inflammatory Bowel Diseases;International Archives of Allergy and Immunology;2024-09-04

2. Non-IgE-mediated drug-induced hypersensitivity reactions in pediatrics;Current Opinion in Pediatrics;2024-08-20

3. Rapid Drug Desensitization and Management of Breakthrough Reactions in Pediatric Patients;ASTHMA ALLERGY IMMUN;2024

4. Targeted Treatment of Diseases of Immune Dysregulation;Rheumatic Disease Clinics of North America;2023-11

5. Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System;BioDrugs;2023-03-06